Telomir Pharmaceuticals (NASDAQ:TELO) Issues Earnings Results, Misses Estimates By $0.05 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) issued its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05), Zacks reports.

Telomir Pharmaceuticals Stock Performance

Shares of TELO stock traded up $0.34 on Tuesday, reaching $4.51. The stock had a trading volume of 128,303 shares, compared to its average volume of 114,327. Telomir Pharmaceuticals has a 1 year low of $3.11 and a 1 year high of $20.72. The company has a 50 day simple moving average of $4.74 and a 200 day simple moving average of $4.81.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.